I-Erlotinib Hydrochloride CAS 183319-69-9 Ubumsulwa >99.0% (HPLC)
Umkhiqizi ohamba phambili nomphakeli we-Erlotinib Hydrochloride Intermediates
I-Erlotinib Hydrochloride CAS 183319-69-9
3-Ethynylaniline CAS 54060-30-9
6,7-Bis(2-Methoxyethoxy)-3H-Quinazolin-4-one CAS 179688-29-0
Please contact: alvin@ruifuchem.com
Igama Lekhemikhali | I-Erlotinib Hydrochloride |
Omqondofana | I-Erlotinib HCl;Tarceva;I-CP-358774 Hydrochloride;I-6,7-Bis(2-methoxyethoxy) -4-(3-ethynylanilino)quinazoline Hydrochloride;N-(3-Ethynylphe nyl)[6,7-bis(2-methoxyethoxy)quinazolin-4-yl]amine HCl |
Inombolo ye-CAS | 183319-69-9 |
Inombolo yeCAT | I-RF-PI2242 |
Isimo Sesitoko | Esitokweni, Isikali Sokukhiqiza Sifinyelela Kumathani |
I-Molecular Formula | I-C22H24ClN3O4 |
Isisindo samangqamuzana | 429.90 |
Ibhrendi | I-Ruifu Chemical |
Into | Imininingwane |
Ukubukeka | I-Crystalline Powder emhlophe ukuya kokumhlophe |
Ukuhlonza | A: IR: Ihambisana ne-Reference Spectrum B: I-HPLC: Ihambisana ne-Reference RT |
Ukuncibilika | Incibilika Kancane Kancane Emanzini, Incibilika Kancane ku-Methanol futhi Ayincibiliki Kakhulu ku-Acetonitrile, i-Acetone, i-Ethyl Acetate ne-Hexane |
I-Melting Point | 223.0~229.0℃ |
Ukulahlekelwa Ekumisweni | <0.50% |
Izinsalela ekushiseni | <0.20% |
Izinsimbi Ezisindayo | <20ppm |
Ukungcola Okukodwa | <0.50% |
Ukungcola Okuphelele | <1.00% |
Izincibilikisi Ezisele | |
I-Pyridine | <4000ppm |
I-Chloroform | <4000ppm |
I-DMF | <3000ppm |
Ukuhlanzeka / Indlela Yokuhlaziya | >99.0% |
Indlela Yokuhlola / Yokuhlaziya | 98.5%~101.0% (Ibalwe Ngokusekelwe I-Anhydrous) |
Izinga Lokuhlola | I-Enterprise Standard |
Ukusetshenziswa | I-API |
Iphakheji: Ibhodlela, isikhwama se-Aluminium foil, 25kg/Cardboard Drum, noma ngokwemfuneko yekhasimende
Isimo Sesitoreji:Gcina ezitsheni ezivaliwe endaweni epholile neyomile;Vikela ekukhanyeni nakumswakama
I-Erlotinib Hydrochloride (i-CAS: 183319-69-9) iyi-molecule encane ye-epidermal growth factor receptor tyrosine kinase reversible inhibitor, isetshenziswa kakhulu ekwelapheni umdlavuza wamaphaphu osethuthuke kakhulu endaweni noma ongewona omncane weseli kanye nomugqa wesibili noma imigqa emithathu yokwelashwa umdlavuza we-pancreatic.I-Erlotinib Hydrochloride yavunywa ngoNovemba, 2004, ukuze yelashwe umdlavuza wamaphaphu othuthukisiwe noma we-metastatic non-smallcell.Ingokwesigaba esifanayo ne-Gefitinib, enye i-quinazoline egunyazwe ukwelashwa komdlavuza wamaphaphu othuthukisiwe, kodwa enezici ze-pharmacokinetic ezithuthukisiwe.I-molecule yasungulwa yi-Pfizer futhi ukuthuthukiswa kwaqalwa ngokubambisana ne-OSI, eyathatha amalungelo aphelele esidakamizwa lapho i-Pfizer ihlanganiswa no-Warner Lambert.Ngokulandelayo, i-Genentech/Roche yangena esivumelwaneni selayisense ne-OSI ukuze ithuthukise futhi imakethe umuthi e-US nasemhlabeni wonke.I-Selective epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitor.I-Antineoplastic.I-Erlotinib Hydrochloride iyi-HER1/EGFR inhibitor ene-IC50 ye-2 nM.I-Erlotinib HCl itholakala njengamaphilisi angama-25-, 100-, kanye ne-150-mg yokuphathwa ngomlomo.